# Semaglutide Starting Dose: 0.25 mg, and What Compounding Changes | This GLP

The starting dose is 0.25 mg weekly for four weeks, escalating every four weeks to 1.7 or 2.4 mg. What compounding changes, and the measurement error that causes harm.

Publisher: This GLP Editorial Team
Canonical: https://thisglp.com/research/semaglutide-starting-dose
Updated: 2026-10-26
Published: 2026-09-17

[← Research](https://thisglp.com/research)

Formats

# Semaglutide Starting Dose: 0.25 mg, and What Compounding Changes

Four weeks at 0.25 mg, then a step every four weeks to 1.7 or 2.4 mg. What changes with a compounded vial is not the milligrams — it is who measures them.

[This GLP Editorial Team](https://thisglp.com/about)September 20267 min read

The labeled ladder — four weeks on every rung · 0.25 · wk 1–4 · 0.5 · wk 5–8 · 1 · wk 9–12 · 1.7 · wk 13–16 · 2.4 · wk 17+ · Milligrams weekly. No compounded product carries this label.

**Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms).

## Key takeaways

-   The labeled starting dose is 0.25 mg once weekly for four weeks — a dose chosen for tolerability, not for weight loss.
-   Escalation steps every four weeks: 0.5 mg, then 1 mg, then 1.7 mg, reaching a maintenance dose of 1.7 or 2.4 mg at week 17.
-   No compounded semaglutide carries an FDA-approved label, so the ladder above is the approved product's, borrowed by convention.
-   The real difference with a compounded vial is not the milligrams. It is that you measure them yourself, in units, on a syringe.

The short answer is 0.25 mg once weekly for the first four weeks. The longer answer has three parts. The number comes from the approved product’s label. No compounded vial has a label of its own. And the step that goes wrong is not choosing the dose. It is drawing it.

## What the labeled ladder actually is

The prescribing information for the approved injection sets a fixed escalation schedule and tells prescribers to titrate every four weeks [\[5\]](https://thisglp.com/research/semaglutide-starting-dose#ref-5). Every rung below is four weeks long.

Recommended starting dosage and escalation, approved semaglutide injection.
| Weeks | Weekly dose | What this rung is for |
| --- | --- | --- |
| 1–4 | 0.25 mg | Starting dosage. Not a treatment dose. |
| 5–8 | 0.5 mg | First escalation step. |
| 9–12 | 1 mg | Second escalation step. |
| 13–16 | 1.7 mg | Third step — also a valid maintenance dose. |
| 17 and onward | 1.7 mg or 2.4 mg | Maintenance for weight reduction. |

Recommended starting dosage and escalation, approved semaglutide injection. FDA prescribing information via DailyMed, read September 2026

Two provisions matter more than the numbers. If a dose is not tolerated, the label says to consider delaying escalation by four weeks rather than pushing on. Miss two or more consecutive weekly doses and escalation restarts at a lower dose. You do not resume where you left off. That second rule catches people who travel, run out, or wait on a refill.

## Why it starts so low

0.25 mg is not a weight-loss dose. It exists to get the gut used to the drug — the reasoning behind [every published ladder](https://thisglp.com/research/who-publishes-a-glp1-dose-ladder). The STEP 1 to 3 trials pooled their gastrointestinal events at 2.4 mg. Nausea ran 43.9% against 16.1% on placebo. Vomiting ran 24.5% against 6.3%. Diarrhea ran 29.7% against 15.9% [\[2\]](https://thisglp.com/research/semaglutide-starting-dose#ref-2). Those events clustered during and shortly after escalation, and 98.1% were mild to moderate.

43.9%

had nausea on 2.4 mg (16.1% on placebo)

STEP 1–3 pooled

98.1%

of gut side effects were mild or moderate

STEP 1–3 pooled

4.3%

stopped permanently because of them

STEP 1–3 pooled

<1 pt

of the weight loss was explained by them

mediation analysis

You do not have to feel sick for it to be working

The same analysis ran a mediation model and found that of the extra 7.6% to 14.4% of weight lost on semaglutide against placebo, less than one percentage point was mediated by gastrointestinal side effects. People who had no side effects lost 9.6% to 17.1%; people who had them lost 11.4% to 17.7%. Feeling unwell is not the mechanism, and tolerating a slower climb costs you very little — which is the reasoning behind [the titration schedule](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1).

## What changes when the product is compounded

The milligrams do not change. The delivery does. An approved product arrives as a pen, with the dose selected for you. A compounded product typically arrives as a vial with syringes. The arithmetic moves to your kitchen table.

A poison-control case series describes what that costs. Of three cases of compounded semaglutide administration errors, two were ten-fold overdoses. All three patients had nausea, vomiting and abdominal pain lasting days. One received a vial and syringes with no pharmacist counseling. One reported dosing in milliliters and units rather than milligrams [\[3\]](https://thisglp.com/research/semaglutide-starting-dose#ref-3). The authors’ conclusion is about the format. Vials do not carry the safety features of a prefilled pen. Syringes not intended for semaglutide make the unit ambiguous.

Your vial's concentration is the number that matters

“How many units is 0.25 mg” has no fixed answer, because it depends entirely on the concentration of the vial in front of you. The same 0.25 mg is a different mark on the syringe at 2.5 mg/mL than at 5 mg/mL. Never carry a unit count over from a previous vial, a forum post or a friend — read the concentration on the label you were dispensed, every time it changes. This is the failure mode behind [the dose errors that reach adverse-event reports](https://thisglp.com/research/glp1-dose-errors-in-adverse-reports).

## Is the compounded version riskier?

One study read the FDA’s adverse event database from 2018 to 2024. It compared 707 reports involving compounded products against 81,078 GLP-1 reports in total [\[4\]](https://thisglp.com/research/semaglutide-starting-dose#ref-4). Compounded products carried higher reporting odds on four counts. Preparation errors: ROR 48.92 (95% CI 12.63 to 189.6). Contamination: 19.00 (4.24 to 85.03). Compounding or manufacturing issues: 8.51 (5.17 to 14.0). Hospitalization: 2.35 (1.94 to 2.83).

The same study found _lower_ reporting odds for administration errors (0.29) and dosing errors (0.24). That runs against the case-series picture. It is worth stating rather than hiding. Reporting odds ratios measure what gets reported, not what happens. A disproportionality signal is not an incidence rate. Read the direction and the intervals, not the point estimates.

## So what should you actually do in week one

Start at the dose your prescriber wrote, which for a first course is almost always 0.25 mg weekly. Read the concentration printed on your vial and have whoever dispensed it confirm the mark on the syringe before the first injection. Hold each rung four weeks. If a rung is rough, the label advises staying there another four weeks rather than climbing. Miss two weeks in a row and expect to step back down. What happens at the top of the ladder is a separate question, covered in [how deep a published dose ladder goes](https://thisglp.com/research/how-deep-a-published-dose-ladder-goes).

This guide will not tell you which concentration to buy. It will not convert milligrams to units for a specific vial. That calculation has a wrong answer, and the wrong answer sends people to hospital. The person dispensing your medication should do it with you.

The [Coby Health review](https://thisglp.com/reviews/coby-health) illustrates how a seller’s [dose and bundle menu](https://www.cobyhealth.com/treatments/weight-loss/semaglutide) differs from a prescription. Prices can be compared before enrollment, but the prescriber must determine your regimen. A package label or discount is not a reason to choose a higher dose or change the instructions supplied with medication.

## Frequently asked

What is the starting dose of compounded semaglutide?

Almost always 0.25 mg once weekly for four weeks, following the approved product's labeled schedule. No compounded semaglutide has an FDA-approved label of its own, so that ladder is borrowed by convention rather than required.

How many units is 0.25 mg?

There is no single answer. It depends on the concentration of your vial — the same 0.25 mg sits at a different mark at 2.5 mg/mL than at 5 mg/mL. Have the pharmacy that dispensed it confirm the mark before your first injection.

How long before I move up to the next dose?

Four weeks on each rung: 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, then maintenance at 1.7 or 2.4 mg from week 17. If a dose is not tolerated, the label advises delaying escalation by another four weeks.

What if I miss a couple of weeks?

If two or more consecutive weekly doses are missed, the label says to reinitiate escalation at a lower dose rather than resume where you stopped.

Is compounded semaglutide more dangerous than the branded product?

Adverse event reports show higher reporting odds of preparation errors, contamination and hospitalization for compounded products, though lower odds of dosing errors. These are disproportionality signals in a voluntary reporting system, not incidence rates.

## Sources

1.  \[1\] Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity The New England Journal of Medicine. [PMID 33567185](https://pubmed.ncbi.nlm.nih.gov/33567185/)
2.  \[2\] Wharton S, Calanna S, Davies M, Dicker D, Goldman B, Lingvay I (2022). Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss Diabetes, Obesity and Metabolism. [PMID 34514682](https://pubmed.ncbi.nlm.nih.gov/34514682/)
3.  \[3\] Lambson JE, Flegal SC, Johnson AR (2023). Administration errors of compounded semaglutide reported to a poison control center-Case series Journal of the American Pharmacists Association. [PMID 37392810](https://pubmed.ncbi.nlm.nih.gov/37392810/)
4.  \[4\] McCall KL, Mastro Dwyer KA, Casey RT, Samana TN, Sulicz EK, Tso SY (2026). Safety analysis of compounded GLP-1 receptor agonists: a pharmacovigilance study using the FDA adverse event reporting system Expert Opinion on Drug Safety. [PMID 40285721](https://pubmed.ncbi.nlm.nih.gov/40285721/)
5.  \[5\] Novo Nordisk (2026). WEGOVY (semaglutide) injection, for subcutaneous use — prescribing information, Table 1 DailyMed, U.S. National Library of Medicine. [Source](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b)

## Where to get it

### Best GLP-1 injections

Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured.

[Compare providers →](https://thisglp.com/best/compounded-semaglutide)

## More in Formats

-   [
    
    Label-approved sites and semaglutide exposure · Abdomen · 2 in. from navel · similar · Thigh · under the skin · similar · Upper arm · under the skin · similar · Blood levels, not weight loss. No trial randomized people to a site.
    
    ### Where Should You Inject Ozempic? Abdomen, Thigh or Arm Gave the Same Exposure
    
    ](https://thisglp.com/research/where-should-you-inject-ozempic)
-   [
    
    Approved: weight management, US, April 2026 · Phase 3 in progress, not approved: · sleep apnea · hypertension · urinary incontinence · osteoarthritis pain · artery disease · A daily tablet, not a peptide, not an injection.
    
    ### Is There a GLP-1 Pill That Works? Two Tablets, Two Different Answers
    
    ](https://thisglp.com/research/does-the-glp1-pill-work-as-well-as-the-injection)
-   [
    
    Where the approval applies · F0 — no fibrosis · F1 — mild · F2 — significant · approved · F3 — advanced · approved · F4 — cirrhosis · Knowing which row you are in requires testing nobody does at a checkout
    
    ### Who Qualifies for Semaglutide for Liver Disease? Fibrosis Stage F2 to F3
    
    ](https://thisglp.com/research/who-qualifies-for-semaglutide-for-liver-disease)